Register for free to
view the full innovation profile.
This combination of drugs is at low doses and can be given orally. Both drugs involved in this combination therapy are FDA approved.
About
Summary Many immunocompromised patients suffer from pulmonary and central nervous system fungal infections caused by pathogens such as C. neoformans. The current standard treatment entails intravenously administrating anti-fungal agents that are extremely toxic. In addition, new structural and mechanistic classes of antifungal therapeutics are needed to improve treatment options and to counter increasing resistance to currently used agents. This invention identifies and validates a novel treatment regime entailing a combination of two drugs.